Biomarkers with Potential Predictive Value for Cardiotoxicity in Anticancer Treatments

Yang Wei; Zhang Mei

doi:10.24920/003790

Your Location：

Home >

Browse articles >

Biomarkers with Potential Predictive Value for Cardiotoxicity in Anticancer Treatments

Chinese Medical Sciences Journal Vol. 36, Issue 4, Pages: 333-341(2021)

Reviews | Updated：2024-04-10

- Biomarkers with Potential Predictive Value for Cardiotoxicity in Anticancer Treatments
- Affiliations：
  
  The Key Laboratory of Cardiovascular Remodeling and Function Research of Chinese Ministry of Education and Chinese Ministry of Health, The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Department of Cardiology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, China
- Author bio：
  
  *Tel: 86-18560086629, E-mail: daixh@vip.sina.com
- Funds：
- DOI：10.24920/003790
  CLC：
- Received：07 June 2020，
  
  Published Online：08 October 2021，
  
  Published：31 December 2021
- Accepted：
Scan QR Code
Yang Wei, Zhang Mei. Biomarkers with Potential Predictive Value for Cardiotoxicity in Anticancer Treatments[J]. Chinese medical sciences journal, 2021, 36(4): 333-341.
DOI：

Yang Wei, Zhang Mei. Biomarkers with Potential Predictive Value for Cardiotoxicity in Anticancer Treatments[J]. Chinese medical sciences journal, 2021, 36(4): 333-341. DOI： 10.24920/003790.

摘要

抗癌治疗在延长肿瘤患者生存期的同时

抗癌治疗引起的各种近期和远期副作用

尤其是心脏毒性显得日益突出。然而

对于恶性肿瘤患者是否会经历心血管并发症

尚无敏感度及特异度极高的早期发现和准确预测手段。炎症、纤维化和氧化应激被认为是抗癌治疗引发心脏毒性的重要机制。相对于临床症状和左室射血分数

相关的心血管生物标志物可能具有更早发现心血管功能紊乱的能力

对于及时肿瘤调整治疗方案以及患者预后评估具有更大价值。临床上

心肌肌钙蛋白T/I和脑钠肽/N-末端脑钠肽前体已被推荐用于常规心脏毒性监测

一些新的生物标志物

如可溶性肿瘤抑制因子-2、髓过氧化物酶、生长分化因子-15、半乳糖凝集素-3、内皮素-1具有潜在的研究价值。在应用于临床之前

需要大样本的试验证实其有效性

同时提高易操作性、降低成本。

Abstract

Rapid development of anticancer treatments in recent years has greatly improved prognosis of cancer patients. However

with extension of survival time of cancer patients

various short-term and long-term side effects brought about by anticancer treatments

especially cardiotoxicity

have become increasingly prominent. Nonetheless

at present

there is few diagnostic methods with extremely high sensitivity and specificity to detect and accurately predict whether patients with anticancer treatment will experience cardiovascular complications. Inflammation

fibrosis and oxidative stress are considered to be important mechanisms involved in cardiotoxicity anticancer treatments. The cardiovascular biomarkers having the ability to predict and detect cardiovascular dysfunction earlier than clinical symptoms as well as left ventricular ejection fraction monitored by echocardiography

are of great value to timely treatment adjustment and prognosis evaluation. Cardiac troponin T/I and brain natriuretic peptide/N-terminal prohormone of brain natriuretic peptide have been routinely used in clinical practice to monitor cardiotoxicity

and some new biomarkers such as soluble suppression of tumorigenecity-2

myeloperoxidase

growth differentiation factor-15

galectin-3

endothelin-1

have potential in this area. In the future

larger-scale experimental studies are needed to provide sufficient evidences

and how to detect them quickly and at low cost is also a problem to be dealed with.

关键词

Keywords

references

Jones DS , Podolsky SH , Greene JA . The burden of disease and the changing task of medicine . N Engl J Med 2012 ; 366 ( 25 ): 2333 - 8 . doi: 10.1056/NEJMp1113569 https://dx.doi.org/10.1056/NEJMp1113569 . DOI: 10.1056/NEJMp1113569 http://doi.org/10.1056/NEJMp1113569 http://www.nejm.org/doi/10.1056/NEJMp1113569 http://www.nejm.org/doi/10.1056/NEJMp1113569

Ferlay J , Steliarova-Foucher E , Lortet-Tieulent J , et al . Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 . Eur J Cancer 2013 ; 49 ( 6 ): 1374 - 403 . doi: 10.1016/j.ejca.2012.12.027 https://dx.doi.org/10.1016/j.ejca.2012.12.027 . DOI: 10.1016/j.ejca.2012.12.027 http://doi.org/10.1016/j.ejca.2012.12.027

Siegel R , DeSantis C , Virgo K , et al . Cancer treatment and survivorship statistics, 2012 . CA Cancer J Clin 2012 ; 62 ( 4 ): 220 - 41 . doi: 10.3322/caac.21149 https://dx.doi.org/10.3322/caac.21149 . DOI: 10.3322/caac.21149 http://doi.org/10.3322/caac.21149 http://doi.wiley.com/10.3322/caac.v62%3A4 http://doi.wiley.com/10.3322/caac.v62%3A4

Ewer MS , Ewer SM . Cardiotoxicity of anticancer treatments . Nat Rev Cardiol 2015 ; 12 ( 9 ): 547 - 58 . doi: 10.1038/nrcardio.2015.65 https://dx.doi.org/10.1038/nrcardio.2015.65 . DOI: 10.1038/nrcardio.2015.65 http://doi.org/10.1038/nrcardio.2015.65 https://doi.org/10.1038/nrcardio.2015.65 https://doi.org/10.1038/nrcardio.2015.65

Zamorano JL , Lancellotti P , Rodriguez MD , et al . 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) . Eur Heart J 2016 ; 37 ( 36 ): 2768 - 801 . doi: 10.1093/eurheartj/ehw211 https://dx.doi.org/10.1093/eurheartj/ehw211 . DOI: 10.1093/eurheartj/ehw211 http://doi.org/10.1093/eurheartj/ehw211

Sawaya H , Sebag IA , Plana JC , et al . Early detection and prediction of cardiotoxicity in chemotherapy-treated patients . Am J Cardiol 2011 ; 107 ( 9 ): 1375 - 80 . doi: 10.1016/j.amjcard.2011.01.006 https://dx.doi.org/10.1016/j.amjcard.2011.01.006 . DOI: 10.1016/j.amjcard.2011.01.006 http://doi.org/10.1016/j.amjcard.2011.01.006 https://linkinghub.elsevier.com/retrieve/pii/S000291491100141X https://linkinghub.elsevier.com/retrieve/pii/S000291491100141X

Ky B , Vejpongsa P , Yeh ET , et al . Emerging paradigms in cardiomyopathies associated with cancer therapies . Circ Res 2013 ; 113 ( 6 ): 754 - 64 . doi: 10.1161/ CIRCRESAHA.113.300218 https://dx.doi.org/10.1161/ CIRCRESAHA.113.300218 . DOI: 10.1161/ CIRCRESAHA.113.300218 http://doi.org/10.1161/ CIRCRESAHA.113.300218 https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.113.300218 https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.113.300218

Octavia Y , Tocchetti CG , Gabrielson KL , et al . Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies . J Mol Cell Cardiol 2012 ; 52 ( 6 ): 1213 - 25 . doi: 10.1016/j.yjmcc.2012.03.006 https://dx.doi.org/10.1016/j.yjmcc.2012.03.006 . DOI: 10.1016/j.yjmcc.2012.03.006 http://doi.org/10.1016/j.yjmcc.2012.03.006

Xu MF , Tang PL , Qian ZM , et al . Effects by doxorubicin on the myocardium are mediated by oxygen free radicals . Life Sci 2001 ; 68 ( 8 ): 889 - 901 . doi: 10.1016/s0024-3205(00)00990-5 https://dx.doi.org/10.1016/s0024-3205(00)00990-5 . DOI: 10.1016/s0024-3205(00)00990-5 http://doi.org/10.1016/s0024-3205(00)00990-5

Lenneman CG , Sawyer DB . Cardio-oncology: an update on cardiotoxicity of cancer-related treatment . Circ Res 2016 ; 118 ( 6 ): 1008 - 20 . doi: 10.1161/CIRCRESAHA. 115.303633 https://dx.doi.org/10.1161/CIRCRESAHA. 115.303633 . DOI: 10.1161/CIRCRESAHA.115.303633 http://doi.org/10.1161/CIRCRESAHA.115.303633

Ylä-Herttuala S , Rissanen TT , Vajanto I , et al . Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine . J Am Coll Cardiol 2007 ; 49 ( 10 ): 1015 - 26 . doi: 10.1016/j.jacc.2006.09.053 https://dx.doi.org/10.1016/j.jacc.2006.09.053 . DOI: 10.1016/j.jacc.2006.09.053 http://doi.org/10.1016/j.jacc.2006.09.053

Morrow DA . The Fourth Universal Definition of Myocardial Infarction and the Emerging Importance of Myocardial Injury . Circulation 2020 ; 141 ( 3 ): 172 - 5 . doi: 10.1161/CIRCULATIONAHA.119.044125 https://dx.doi.org/10.1161/CIRCULATIONAHA.119.044125 . DOI: 10.1161/CIRCULATIONAHA.119.044125 http://doi.org/10.1161/CIRCULATIONAHA.119.044125

Shah KS , Yang EH , Maisel AS , et al . The role of biomarkers in detection of cardio-toxicity . Curr Oncol Rep 2017 ; 19 ( 6 ): 42 . doi: 10.1007/s11912-017-0602-9 https://dx.doi.org/10.1007/s11912-017-0602-9 . DOI: 10.1007/s11912-017-0602-9 http://doi.org/10.1007/s11912-017-0602-9 http://link.springer.com/10.1007/s11912-017-0602-9 http://link.springer.com/10.1007/s11912-017-0602-9

Eggers KM , Lindahl B . Application of cardiac troponin in cardiovascular diseases other than acute coronary syndrome . Clin Chem 2017 ; 63 ( 1 ): 223 - 35 . doi: 10.1373/clinchem.2016.261495 https://dx.doi.org/10.1373/clinchem.2016.261495 . DOI: 10.1373/clinchem.2016.261495 http://doi.org/10.1373/clinchem.2016.261495

Michel L , Mincu RI , Mahabadi AA , et al . Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis . Eur J Heart Fail 2020 ; 22 ( 2 ): 350 - 61 . doi: 10.1002/ejhf.1631 https://dx.doi.org/10.1002/ejhf.1631 . DOI: 10.1002/ejhf.1631 http://doi.org/10.1002/ejhf.1631

Demissei BG , Hubbard RA , Zhang L , et al . Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction . J Am Heart Assoc 2020 ; 9 ( 2 ): e014708 . doi: 10.1161/JAHA.119.014708 https://dx.doi.org/10.1161/JAHA.119.014708 . DOI: 10.1161/JAHA.119.014708 http://doi.org/10.1161/JAHA.119.014708

Cardinale D , Ciceri F , Latini R , et al . Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-One trial . Eur J Cancer 2018 ; 94 : 126 - 37 . doi: 10.1016/j.ejca.2018.02.005 https://dx.doi.org/10.1016/j.ejca.2018.02.005 . DOI: S0959-8049(18)30174-6 http://doi.org/S0959-8049(18)30174-6

Curigliano G , Cardinale D , Dent S , et al . Cardiotoxicity of anticancer treatments: epidemiology, detection, and management . CA Cancer J Clin 2016 ; 66 ( 4 ): 309 - 25 . doi: 10.3322/caac.21341 https://dx.doi.org/10.3322/caac.21341 . DOI: 10.3322/caac.21341 http://doi.org/10.3322/caac.21341 http://doi.wiley.com/10.3322/caac.v66.4 http://doi.wiley.com/10.3322/caac.v66.4

Curigliano G , Lenihan D , Fradley M , et al . Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations . Ann Oncol 2020 ; 31 ( 2 ): 171 - 90 . doi: 10.1016/j.annonc.2019.10.023 https://dx.doi.org/10.1016/j.annonc.2019.10.023 . DOI: S0923-7534(19)36080-6 http://doi.org/S0923-7534(19)36080-6

Hall C . NT-ProBNP: the mechanism behind the marker . J Card Fail 2005 ; 11 ( 5 Suppl ): S81 - 3 . doi: 10.1016/j.cardfail.2005.04.019 https://dx.doi.org/10.1016/j.cardfail.2005.04.019 . DOI: 10.1016/j.cardfail.2005.04.019 http://doi.org/10.1016/j.cardfail.2005.04.019 https://linkinghub.elsevier.com/retrieve/pii/S1071916405001843 https://linkinghub.elsevier.com/retrieve/pii/S1071916405001843

Yang S , Huang S , Daniels LB , et al . NT-proBNP, race and endothelial function in the Multi-Ethnic Study of Atherosclerosis . Heart 2019 ; 105 ( 20 ): 1590 - 6 . doi: 10.1136/heartjnl-2019-314707 https://dx.doi.org/10.1136/heartjnl-2019-314707 . DOI: 10.1136/heartjnl-2019-314707 http://doi.org/10.1136/heartjnl-2019-314707 https://heart.bmj.com/lookup/doi/10.1136/heartjnl-2019-314707 https://heart.bmj.com/lookup/doi/10.1136/heartjnl-2019-314707

Putt M , Hahn VS , Januzzi JL , et al . Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab . Clin Chem 2015 ; 61 ( 9 ): 1164 - 72 . doi: 10.1373/clinchem.2015.241232 https://dx.doi.org/10.1373/clinchem.2015.241232 . DOI: 10.1373/clinchem.2015.241232 http://doi.org/10.1373/clinchem.2015.241232 https://academic.oup.com/clinchem/article/61/9/1164/5611513 https://academic.oup.com/clinchem/article/61/9/1164/5611513

Virani SA , Dent S , Brezden-Masley C , et al . Canadian Cardiovascular Society Guidelines for evaluation and management of cardiovascular complications of cancer therapy . Can J Cardiol 2016 ; 32 ( 7 ): 831 - 41 . doi: 10.1016/j.cjca.2016.02.078 https://dx.doi.org/10.1016/j.cjca.2016.02.078 . DOI: 10.1016/j.cjca.2016.02.078 http://doi.org/10.1016/j.cjca.2016.02.078

Kakkar R , Lee RT . The IL-33/ST2 pathway: therapeutic target and novel biomarker . Nat Rev Drug Discov 2008 ; 7 ( 10 ): 827 - 40 . doi: 10.1038/nrd2660 https://dx.doi.org/10.1038/nrd2660 . DOI: 10.1038/nrd2660 http://doi.org/10.1038/nrd2660

Morin DP , Chong-Yik R , Thihalolipavan S , et al . Utility of serial measurement of biomarkers of cardiovascular stress and inflammation in systolic dysfunction . Europace 2020 ; 22 ( 7 ): 1044 - 53 . doi: 10.1093/europace/euaa075 https://dx.doi.org/10.1093/europace/euaa075 . DOI: 10.1093/europace/euaa075 http://doi.org/10.1093/europace/euaa075 https://academic.oup.com/europace/article/22/7/1044/5827825 https://academic.oup.com/europace/article/22/7/1044/5827825

Aimo A , Januzzi JL , Vergaro G , et al . Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T . Eur J Heart Fail 2020 ; 22 ( 11 ): 2078 - 88 . doi: 10.1002/ejhf.1701 https://dx.doi.org/10.1002/ejhf.1701 . DOI: 10.1002/ejhf.1701 http://doi.org/10.1002/ejhf.1701 https://onlinelibrary.wiley.com/toc/18790844/22/11 https://onlinelibrary.wiley.com/toc/18790844/22/11

Zagidullin N , Motloch LJ , Gareeva D , et al . Combining novel biomarkers for risk stratification of two-year cardiovascular mortality in patients with ST-elevation myocardial infarction . J Clin Med 2020 ; 9 ( 2 ): 550 . doi: 10.3390/jcm9020550 https://dx.doi.org/10.3390/jcm9020550 . DOI: 10.3390/jcm9020550 http://doi.org/10.3390/jcm9020550 https://www.mdpi.com/2077-0383/9/2/550 https://www.mdpi.com/2077-0383/9/2/550

Frères P , Bouznad N , Servais L , et al . Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients . BMC Cancer 2018 ; 18 ( 1 ): 102 . doi: 10.1186/s12885-018-4015-4 https://dx.doi.org/10.1186/s12885-018-4015-4 . DOI: 10.1186/s12885-018-4015-4 http://doi.org/10.1186/s12885-018-4015-4 https://doi.org/10.1186/s12885-018-4015-4 https://doi.org/10.1186/s12885-018-4015-4

Aula H , Skyttä T , Tuohinen S , et al . ST2 levels increased and were associated with changes in left ventricular systolic function during a three-year follow-up after adjuvant radiotherapy for breast cancer . Breast 2020 ; 49 : 183 - 6 . doi: 10.1016/j.breast.2019.12.001 https://dx.doi.org/10.1016/j.breast.2019.12.001 . DOI: 10.1016/j.breast.2019.12.001 http://doi.org/10.1016/j.breast.2019.12.001 https://linkinghub.elsevier.com/retrieve/pii/S0960977619311063 https://linkinghub.elsevier.com/retrieve/pii/S0960977619311063

Tang WH , Tong W , Troughton RW , et al . Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure . J Am Coll Cardiol 2007 ; 49 ( 24 ): 2364 - 70 . doi: 10.1016/j.jacc.2007.02.053 https://dx.doi.org/10.1016/j.jacc.2007.02.053 . DOI: 10.1016/j.jacc.2007.02.053 http://doi.org/10.1016/j.jacc.2007.02.053 https://linkinghub.elsevier.com/retrieve/pii/S0735109707011205 https://linkinghub.elsevier.com/retrieve/pii/S0735109707011205

Odobasic D , Kitching AR , Holdsworth SR . Neutrophil-mediated regulation of innate and adaptive immunity: the role of myeloperoxidase . J Immunol Res 2016 ; 2016 : 2349817 . doi: 10.1155/2016/2349817 https://dx.doi.org/10.1155/2016/2349817 . DOI: 10.1155/2016/2349817 http://doi.org/10.1155/2016/2349817

Abdo AI , Rayner BS , van Reyk DM , et al . Low-density lipoprotein modified by myeloperoxidase oxidants induces endothelial dysfunction . Redox Biol 2017 ; 13 : 623 - 32 . doi: 10.1016/j.redox.2017.08.004 https://dx.doi.org/10.1016/j.redox.2017.08.004 . DOI: 10.1016/j.redox.2017.08.004 http://doi.org/10.1016/j.redox.2017.08.004 https://linkinghub.elsevier.com/retrieve/pii/S2213231717304810 https://linkinghub.elsevier.com/retrieve/pii/S2213231717304810

Love DT , Barrett TJ , White MY , et al . Cellular targets of the myeloperoxidase-derived oxidant hypothiocyanous acid (HOSCN) and its role in the inhibition of glycolysis in macrophages . Free Radic Biol Med 2016 ; 94 : 88 - 98 . doi: 10.1016/j.freeradbiomed.2016.02.016 https://dx.doi.org/10.1016/j.freeradbiomed.2016.02.016 . DOI: 10.1016/j.freeradbiomed.2016.02.016 http://doi.org/10.1016/j.freeradbiomed.2016.02.016 https://linkinghub.elsevier.com/retrieve/pii/S0891584916000678 https://linkinghub.elsevier.com/retrieve/pii/S0891584916000678

Ndrepepa G . Myeloperoxidase—a bridge linking inflammation and oxidative stress with cardiovascular disease . Clin Chim Acta 2019 ; 493 : 36 - 51 . doi: 10.1016/j.cca.2019.02.022 https://dx.doi.org/10.1016/j.cca.2019.02.022 . DOI: S0009-8981(19)30084-1 http://doi.org/S0009-8981(19)30084-1

Baldus S , Heeschen C , Meinertz T , et al . Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes . Circulation 2003 ; 108 ( 12 ): 1440 - 5 . doi: 10.1161/01.CIR.0000090690.67322.51 https://dx.doi.org/10.1161/01.CIR.0000090690.67322.51 . DOI: 10.1161/01.CIR.0000090690.67322.51 http://doi.org/10.1161/01.CIR.0000090690.67322.51 https://www.ahajournals.org/doi/10.1161/01.CIR.0000090690.67322.51 https://www.ahajournals.org/doi/10.1161/01.CIR.0000090690.67322.51

Finkelman BS , Putt M , Wang T , et al . Arginine-nitric oxide metabolites and cardiac dysfunction in patients with breast cancer . J Am Coll Cardiol 2017 ; 70 ( 2 ): 152 - 62 . doi: 10.1016/j.jacc.2017.05.019 https://dx.doi.org/10.1016/j.jacc.2017.05.019 . DOI: S0735-1097(17)37364-3 http://doi.org/S0735-1097(17)37364-3

Gullo G , J EA , Canonici A , et al . Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial . Ther Adv Med Oncol 2019 ; 11 : 1758835919864236 . doi: 10.1177/1758835919864236 https://dx.doi.org/10.1177/1758835919864236 . DOI: 10.1177/1758835919864236 http://doi.org/10.1177/1758835919864236

Bootcov MR , Bauskin AR , Valenzuela SM , et al . MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily . Proc Natl Acad Sci USA 1997 ; 94 ( 21 ): 11514 - 9 . doi: 10.1073/pnas.94.21.11514 https://dx.doi.org/10.1073/pnas.94.21.11514 . DOI: 10.1073/pnas.94.21.11514 http://doi.org/10.1073/pnas.94.21.11514 http://www.pnas.org/cgi/doi/10.1073/pnas.94.21.11514 http://www.pnas.org/cgi/doi/10.1073/pnas.94.21.11514

Xu XY , Nie Y , Wang FF , et al . Growth differentiation factor (GDF)-15 blocks norepinephrine-induced myocardial hypertrophy via a novel pathway involving inhibition of epidermal growth factor receptor transactivation . J Biol Chem 2014 ; 289 ( 14 ): 10084 - 94 . doi: 10.1074/jbc.M113.516278 https://dx.doi.org/10.1074/jbc.M113.516278 . DOI: 10.1074/jbc.M113.516278 http://doi.org/10.1074/jbc.M113.516278 https://linkinghub.elsevier.com/retrieve/pii/S0021925820420708 https://linkinghub.elsevier.com/retrieve/pii/S0021925820420708

Wollert KC , Kempf T , Wallentin L . Growth differentiation factor 15 as a biomarker in cardiovascular disease . Clin Chem 2017 ; 63 ( 1 ): 140 - 51 . doi: 10.1373/clinchem.2016.255174 https://dx.doi.org/10.1373/clinchem.2016.255174 . DOI: 10.1373/clinchem.2016.255174 http://doi.org/10.1373/clinchem.2016.255174

Bouabdallaoui N , Claggett B , Zile MR , et al . Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial . Eur J Heart Fail 2018 ; 20 ( 12 ): 1701 - 9 . doi: 10.1002/ejhf.1301 https://dx.doi.org/10.1002/ejhf.1301 . DOI: 10.1002/ejhf.1301 http://doi.org/10.1002/ejhf.1301

Stenemo M , Nowak C , Byberg L , et al . Circulating proteins as predictors of incident heart failure in the elderly . Eur J Heart Fail 2018 ; 20 ( 1 ): 55 - 62 . doi: 10.1002/ejhf.980 https://dx.doi.org/10.1002/ejhf.980 . DOI: 10.1002/ejhf.980 http://doi.org/10.1002/ejhf.980

Hagström E , James SK , Bertilsson M , et al . Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study . Eur Heart J 2016 ; 37 ( 16 ): 1325 - 33 . doi: 10.1093/eurheartj/ehv491 https://dx.doi.org/10.1093/eurheartj/ehv491 . DOI: 10.1093/eurheartj/ehv491 http://doi.org/10.1093/eurheartj/ehv491

Lindholm D , James SK , Gabrysch K , et al . Association of multiple biomarkers with risk of all-cause and cause-specific mortality after acute coronary syndromes: a secondary analysis of the PLATO biomarker study . JAMA Cardiol 2018 ; 3 ( 12 ): 1160 - 6 . doi: 10.1001/jamacardio.2018.3811 https://dx.doi.org/10.1001/jamacardio.2018.3811 . DOI: 10.1001/jamacardio.2018.3811 http://doi.org/10.1001/jamacardio.2018.3811

Tromp J , Boerman LM , Sama IE , et al . Long-term survivors of early breast cancer treated with chemotherapy are characterized by a pro-inflammatory biomarker profile compared to matched controls . Eur J Heart Fail 2020 ; 22 ( 7 ): 1239 - 46 . doi: 10.1002/ejhf.1758 https://dx.doi.org/10.1002/ejhf.1758 . DOI: 10.1002/ejhf.1758 http://doi.org/10.1002/ejhf.1758 https://onlinelibrary.wiley.com/toc/18790844/22/7 https://onlinelibrary.wiley.com/toc/18790844/22/7

Ky B , Putt M , Sawaya H , et al . Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab . J Am Coll Cardiol 2014 ; 63 ( 8 ): 809 - 16 . doi: 10.1016/j.jacc.2013.10.061 https://dx.doi.org/10.1016/j.jacc.2013.10.061 . DOI: 10.1016/j.jacc.2013.10.061 http://doi.org/10.1016/j.jacc.2013.10.061 https://linkinghub.elsevier.com/retrieve/pii/S0735109713061573 https://linkinghub.elsevier.com/retrieve/pii/S0735109713061573

Suthahar N , Meijers WC , HHW S , et al . From inflammation to fibrosis-molecular and cellular mechanisms of myocardial tissue remodelling and perspectives on differential treatment opportunities . Curr Heart Fail Rep 2017 ; 14 ( 4 ): 235 - 50 . doi: 10.1007/s11897-017-0343-y https://dx.doi.org/10.1007/s11897-017-0343-y . DOI: 10.1007/s11897-017-0343-y http://doi.org/10.1007/s11897-017-0343-y

Zile MR , O’Meara E , Claggett B , et al . Effects of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF . J Am Coll Cardiol 2019 ; 73 ( 7 ): 795 - 806 . doi: 10.1016/j.jacc.2018.11.042 https://dx.doi.org/10.1016/j.jacc.2018.11.042 . DOI: 10.1016/j.jacc.2018.11.042 http://doi.org/10.1016/j.jacc.2018.11.042

Ghorbani A , Bhambhani V , Christenson RH , et al . Longitudinal change in galectin-3 and incident cardiovascular outcomes . J Am Coll Cardiol 2018 ; 72 ( 25 ): 3246 - 54 . doi: 10.1016/j.jacc.2018.09.076 https://dx.doi.org/10.1016/j.jacc.2018.09.076 . DOI: S0735-1097(18)38906-X http://doi.org/S0735-1097(18)38906-X

Kosmala W , Przewlocka-Kosmala M , Rojek A , et al . Comparison of the diastolic stress test with a combined resting echocardiography and biomarker approach to patients with exertional dyspnea: diagnostic and prognostic implications . JACC Cardiovasc Imaging 2019 ; 12 ( 5 ): 771 - 80 . doi: 10.1016/j.jcmg. 2017.10.008 https://dx.doi.org/10.1016/j.jcmg. 2017.10.008 . DOI: 10.1016/j.jcmg. 2017.10.008 http://doi.org/10.1016/j.jcmg. 2017.10.008 https://linkinghub.elsevier.com/retrieve/pii/S1936878X1730983X https://linkinghub.elsevier.com/retrieve/pii/S1936878X1730983X

Mortensen MB , Fuster V , Muntendam P , et al . Negative risk markers for cardiovascular events in the elderly . J Am Coll Cardiol 2019 ; 74 ( 1 ): 1 - 11 . doi: 10.1016/j.jacc.2019.04.049 https://dx.doi.org/10.1016/j.jacc.2019.04.049 . DOI: S0735-1097(19)35149-6 http://doi.org/S0735-1097(19)35149-6

Tanaka R , Umemura M , Narikawa M , et al . Reactive fibrosis precedes doxorubicin-induced heart failure through sterile inflammation . ESC Heart Fail 2020 ; 7 ( 2 ): 588 - 603 . doi: 10.1002/ehf2.12616 https://dx.doi.org/10.1002/ehf2.12616 . DOI: 10.1002/ehf2.12616 http://doi.org/10.1002/ehf2.12616

van Boxtel W , Bulten BF , Mavinkurve-Groothuis AM , et al . New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide . Biomarkers 2015 ; 20 ( 2 ): 143 - 8 . doi: 10.3109/1354750X.2015.1040839 https://dx.doi.org/10.3109/1354750X.2015.1040839 . DOI: 10.3109/1354750X.2015.1040839 http://doi.org/10.3109/1354750X.2015.1040839

Groarke JD , Nguyen PL , Nohria A , et al . Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease . Eur Heart J 2014 ; 35 ( 10 ): 612 - 23 . doi: 10.1093/eurheartj/eht114 https://dx.doi.org/10.1093/eurheartj/eht114 . DOI: 10.1093/eurheartj/eht114 http://doi.org/10.1093/eurheartj/eht114

Lenihan DJ , Cuculich P . Cardioprotection during therapeutic radiation treatment . Circ Heart Fail 2018 ; 11 ( 8 ): e005294 . doi: 10.1161/CIRCHEARTFAILURE. 118.005294 https://dx.doi.org/10.1161/CIRCHEARTFAILURE. 118.005294 . DOI: 10.1161/CIRCHEARTFAILURE. 118.005294 http://doi.org/10.1161/CIRCHEARTFAILURE. 118.005294

Yanagisawa M , Kurihara H , Kimura S , et al . A novel potent vasoconstrictor peptide produced by vascular endothelial cells . Nature 1988 ; 332 ( 6163 ): 411 - 5 . doi: 10.1038/332411a0 https://dx.doi.org/10.1038/332411a0 . DOI: 10.1038/332411a0 http://doi.org/10.1038/332411a0 https://doi.org/10.1038/332411a0 https://doi.org/10.1038/332411a0

Suzuki T , Kumazaki T , Mitsui Y . Endothelin-1 is produced and secreted by neonatal rat cardiac myocytes in vitro . Biochem Biophys Res Commun 1993 ; 191 ( 3 ): 823 - 30 . doi: 10.1006/bbrc.1993.1291 https://dx.doi.org/10.1006/bbrc.1993.1291 . DOI: 10.1006/bbrc.1993.1291 http://doi.org/10.1006/bbrc.1993.1291 https://linkinghub.elsevier.com/retrieve/pii/S0006291X8371291X https://linkinghub.elsevier.com/retrieve/pii/S0006291X8371291X

Ishikawa T , Yanagisawa M , Kimura S , et al . Positive inotropic action of novel vasoconstrictor peptide endothelin on guinea pig atria . Am J Physiol 1988 ; 255 ( 4 Pt 2 ): H970 - 3 . doi: 10.1152/ajpheart.1988.255.4.H970 https://dx.doi.org/10.1152/ajpheart.1988.255.4.H970 . DOI: 10.1152/ajpheart.1988.255.4.H970 http://doi.org/10.1152/ajpheart.1988.255.4.H970

Luu AZ , Chowdhury B , Al-Omran M , et al . Role of endothelium in doxorubicin-induced cardiomyopathy . JACC Basic Transl Sci 2018 ; 3 ( 6 ): 861 - 70 . doi: 10.1016/j.jacbts.2018.06.005 https://dx.doi.org/10.1016/j.jacbts.2018.06.005 . DOI: 10.1016/j.jacbts.2018.06.005 http://doi.org/10.1016/j.jacbts.2018.06.005

Schwebe M , Ameling S , Hammer E , et al . Protective effects of endothelin receptor A and B inhibitors against doxorubicin-induced cardiomyopathy . Biochem Pharmacol 2015 ; 94 ( 2 ): 109 - 29 . doi: 10.1016/j.bcp.2015.01.014 https://dx.doi.org/10.1016/j.bcp.2015.01.014 . DOI: 10.1016/j.bcp.2015.01.014 http://doi.org/10.1016/j.bcp.2015.01.014 https://linkinghub.elsevier.com/retrieve/pii/S0006295215000830 https://linkinghub.elsevier.com/retrieve/pii/S0006295215000830

Views

526

Downloads

CSCD

Alert me when the article has been cited

Submit

Publicity Resources

Regional Differences of the Urinary Proteomes in Healthy Chinese Individuals

Related Author

Wu Jianqiang

Qin Weiwei

Pan Li

Wang Xiaorong

Zhang Biao

Shan Guangliang

Gao Youhe

Related Institution

Medical Research Center, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences

Department of Pathophysiology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & School of Basic Medicine, Peking Union Medical College

Department of Biochemistry and Molecular Biology, Gene Engineering Drug and Biotechnology Beijing Key Laboratory, Beijing Normal University

Department of Epidemiology and Statistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & School of Basic Medicine, Peking Union Medical College

⁰